Answers are grounded in this paper and cite their sources.
Neurodevelopmental disorders (NDDs) are among the most common reasons for genetic consultation. Managing affected children is complex and requires careful clinical evaluation. Despite advances in next-generation sequencing, timely and accurate diagnosis remains difficult because of phenotypic heterogeneity and challenges in variant interpretation. We therefore explored a clinically oriented framework that classifies Human Phenotype Ontology (HPO) terms according to their potential discriminative value during phenotype documentation and variant interpretation in NDDs undergoing NGS. We examined the HPO term “neurodevelopmental abnormality” (HP:0012759) and its 47 descendant terms. The terms were classified into four tiers: Tier 0 terms had no current gene-disease associations, whereas Tier 1 terms had comparatively few associations and may be more discriminative when confidently observed. Although frequent, Tier 2 and Tier 3 terms were generally less specific. We used four illustrative NDD cases to show how the selection of more or less specific HPO terms may influence clinical interpretation of genomic findings. This tiered classification is intended as a clinical annotation framework to support the selection and communication of informative HPO terms, not as a new prioritization algorithm. The analyses of “abnormality of mental function” (HP:0011446) and “abnormality of the face” (HP:0000271) further illustrate how the same clinical principle can be applied to additional phenotypic domains. The proposed HPO-based tiered classification may help clinicians document and communicate the potential discriminative value of phenotypic features during the clinical consultation and report them to the diagnostic laboratory for variant interpretation in NDDs.
No takes yet. Share an insight, caveat, or question.
Falco et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: